How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

594 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Androgenic alopecia

Androgenic alopecia Androgenic alopecia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Androgenic alopecia Last reviewed: February 2019 Last updated: March 2018 Summary Also known as pattern baldness, androgenic alopecia is a genetically determined, patterned, progressive loss of hair from the scalp and occurs in both men and women. Both androgens and genetics play a role in its pathogenesis. The term androgenic (...) alopecia is best used only when referring to male-pattern hair loss, as most females likely do not share the androgenic pathway. A more appropriate term for women is female-pattern hair loss. The term pattern hair loss will be used when referring to hair loss affecting both sexes. Men present with hair thinning in the temporal areas that advances to the crown (vertex) area as the alopecia progresses. Women usually have more diffuse thinning on the crown area, and less commonly present with a male-type

2018 BMJ Best Practice

2. Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia. (PubMed)

Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia. 5α-DHT can decrease the cell viability of the hair follicle stem cells (HFSCs) with CD34-positive and CD200-rich in bald scalp area of androgenic alopecia (AGA) patients and the apoptosis of HFSCs may be involved in the pathogenesis of AGA. The expression of Vascular (...) apoptosis down substantially in a concentration-dependent manner. The 5α-DHT induced decline in the rise of Bcl-2/Bax proportion and the increase in caspase-3 degrees were mostly reversed by using VEGF and the VEGF's anti-apoptotic actions were impeded through preventing the activation of phosphoinositide 3-kinase (PI3K)/Akt.Vascular endothelial growth factor can protect CD200-rich and CD34-positive HFSCs from androgen induced apoptosis by means of the PI3K/Akt pathway.

2019 Dermatologic Surgery

3. Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men (Full text)

Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men BACKGROUND Androgenic alopecia (AGA) is the most common type of hair loss in men. However, the pathogenesis is not yet fully understood and therapeutic approaches are limited. This retrospective study investigated the association between levels of androgen-associated hormones and curative effect in androgenic alopecia in young male AGA patients. MATERIAL AND METHODS By using (...) chemiluminescence immunoassay, serum levels of androgens and upstream regulated hormones were measured in 178 young male patients with AGA and in 61 normal controls before therapy, 1 and 2 weeks after administration of finasteride. RESULTS Before oral finasteride therapy, we found significantly higher levels of serum free testosterone (FT) and dihydrotestosterone (DHT) in AGA patients than in normal controls. The levels of serum sex hormone-binding globulin (SHBG), luteinizing hormone (LH), and follicle

2018 Medical science monitor : international medical journal of experimental and clinical research PubMed

4. Injections of Platelet-Rich Plasma for androgenic alopecia: A systematic review. (PubMed)

Injections of Platelet-Rich Plasma for androgenic alopecia: A systematic review. The aim of this literature review was to evaluate the effects of PRP injections into the scalp of patients with androgenic alopecia. A literature review was conducted using the Pubmed and Google Scholar databases with the search terms "platelet-rich plasma" or "platelet-rich fibrin" and "hair" or "alopecia" or "androgenic alopecia". The publications included had to clinically assess the efficacy of PRP injections (...) in patients with androgenic alopecia. Out of the 32 publications retrieved, 14 publications were included, of which 3 randomized, 4 prospective controlled, 4 prospective uncontrolled and 3 retrospective studies. Seven out of 9 studies reported a significant increase of hair density ranging between 12.3 and 45.9 hairs/cm2, (i.e. 19-31% hairs/cm2). Four studies assessed hair loss with the traction test and found a negative result after treatment in more than 95% of patients. Regarding hair thickness, 1

2017 Journal of stomatology, oral and maxillofacial surgery

5. Herbal Medicines For Treatment of Androgenic Alopecia. (PubMed)

Herbal Medicines For Treatment of Androgenic Alopecia. Androgenic alopecia is a common and unpleasant problem that directly influences the self-confidence and individual life quality. There are various treatment choices that currently are used by people suffering from androgenic alopecia. Drug therapies (e. g. minoxidil, finasteride, dutasteride, prostaglandin analogues, ketoconazole, Cyproterone acetate and spironolactone), Laser-light treatment, surgical treatment, cell mediated treatment (...) and alternative treatments (vitamin, mineral and herbal components) are common therapeutic methods suggested for management of androgenic alopecia. Herbal medicines are now commonly used all over the world and this has increased global demand. Quality, safety and efficacy of these drugs have become a serious concern.The aim of this review is evaluating the herbal or fungal medicines were used in androgenic alopecia and introducing the phytochemicals, biological effects, responsible constituents

2019 Alternative Therapies in Health & Medicine

6. A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. (PubMed)

A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. Androgenic alopecia (AGA) is a common hair loss disorder. Studies have demonstrated successful treatment with platelet-rich plasma (PRP) in men, but studies in women are few.To evaluate PRP in the treatment of AGA in women, compared with topical minoxidil.Twenty women with AGA received topical minoxidil for 12 weeks and injectable PRP for 12 weeks

2019 Dermatologic Surgery

7. A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. (PubMed)

A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. 5% minoxidil solution is approved for the treatment of male androgenetic alopecia (AGA). However, there have been occasional reports of adverse events that were caused mostly by propylene glycol sensitivity. As an alternative treatment, Siriraj hair team developed a proprietary preparation referred to as “minoxidil milky lotion” that uses

2018 Journal of the Medical Association of Thailand = Chotmaihet thangphaet

8. Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. (PubMed)

Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. Androgenetic alopecia (AGA), the most common cause of hair loss in both sexes, accounts for 95% of all cases of hair loss. Although the literature has suggested that both nonactivated (n-PRP) and activated autologous (a-PRP) PRP can be used to treat AGA, we did not find any study investigating the use of homologous PRP (h-PRP) for this purpose. Also, to the best of our knowledge

2018 Aesthetic plastic surgery

9. Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. (Full text)

Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. A number of studies have investigated the association between androgenic alopecia (AGA) and cancer risk, but they have yielded inconsistent results. Therefore, this study was conducted to explore this controversial subject.A literature database search was performed according to predefined criteria. An odds ratio (OR) or a hazard ratio (HR) with 95

2018 BMC Cancer PubMed

10. Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03676400 Recruitment Status : Recruiting First Posted : September 18, 2018 Last Update Posted

2018 Clinical Trials

11. Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03474718 Recruitment Status : Not yet

2018 Clinical Trials

12. Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03488108 Recruitment Status : Active, not recruiting First Posted : April 4, 2018 Last Update Posted : July 2, 2018 Sponsor: Mayo Clinic

2018 Clinical Trials

13. The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients.

The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients. The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. The Effect of Microneedling With Low Energy Laser in Androgenic Alopecia Patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03723369 Recruitment Status : Recruiting First Posted : October 29, 2018 Last

2018 Clinical Trials

14. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia (Full text)

Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS).To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PFS.AR polymorphisms were studied

2016 Sexual Medicine PubMed

15. Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. (Full text)

Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. The etiology of androgenic alopecia (AGA) involves several factors, including genetics, androgens, age and nutrition. Digit-length ratio of the index and ring finger (2D:4D) is an indicator of prenatal exposure to sex hormones. There is a paucity of studies that systemically review the possible positive predictive value (...) a multifactorial disease. Further, our findings suggest that increased in utero exposure to androgens as a fetus does not predispose men to develop AGA.

2016 Dermatology Reports PubMed

16. Comparison of the effects of 665 nm low level diode Laser Hat versus and a combination of 665 nm and 808nm low level diode Laser Scanner of hair growth in androgenic alopecia. (PubMed)

Comparison of the effects of 665 nm low level diode Laser Hat versus and a combination of 665 nm and 808nm low level diode Laser Scanner of hair growth in androgenic alopecia. This study aimed to evaluate the effectiveness of a combined set of low level diode laser scanner (665 nm and 808nm) on hair growth, and assessment of safety and effectiveness of a new laser scanner on hair growth treatment procedure in androgenic alopecia.90 patients (18 to 70 years) with androgenic alopecia were

2017 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

17. Serum androgens and PSA levels in androgenetic alopecia - is there a difference between frontal and vertex baldness? (PubMed)

Serum androgens and PSA levels in androgenetic alopecia - is there a difference between frontal and vertex baldness? Androgenetic alopecia (AGA) seems to be a marker of increased risk of prostate cancer (PCa).We sought to investigate potential pathophysiological differences between frontal and vertex balding that might have the impact on the incidence of PCa.Serum concentrations of testosterone (T), dihydrotestosterone (DHT) and prostate-specific antigen (PSA) were measured in 88 subjects (...) was found between the serum PSA level and serum androgen levels as well as DHT/T ratio.Vertex baldness may signal higher exposures to circulating DHT. Serum PSA level cannot serve as surrogate diagnostic marker of increased androgenic activity in men with AGA.© 2017 European Academy of Dermatology and Venereology.

2017 Journal of the European Academy of Dermatology and Venereology

18. Systematic review of low-level laser therapy for adult androgenic alopecia.

Systematic review of low-level laser therapy for adult androgenic alopecia. Alopecia is a common disorder affecting over half of the world's population. Within this condition, androgenic alopecia (AA) is the most common type, affecting 50% of males over 40 and 75% of females over 65. Anecdotal paradoxical hypertrichosis noted during laser epilation has generated interest in the possibility of using laser to stimulate hair growth. In this study, we aimed to critically appraise the application

2017 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

19. Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review.

Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. Alopecia is a common disease affecting more than half of the world total number of people. Alopecia exists in different types, but one of the most common of these types is the Androgenic Alopecia which has affected approximately 51% of the total number of males ranging between the age bracket of 40 years and 75 years. This type of alopecia is more common in females who are above the age of 65 (...) for the invention for more efficient management and treatment options that are less costly, environmentally friendly, and most importantly human consumption friendly. Due to the recent evaluation that low-level laser therapy stimulated hair growth. This systematic review and meta-analysis was to determine whether the use of low-level laser therapy is an effective therapy for treatment of the Androgenic alopecia and also to some degree we reviewed the level of the patient's satisfaction. Some earlier studies had

2017 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology

20. Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report (Full text)

Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report In this report we address an unusual adverse effect of finasteride (Propecia 1 mg tablets) that was associated with painless hematuria and hematospermia in a 38-year-old healthy male during treatment of androgenic alopecia at a dose of 1 mg/day. It was found that the bleeding was linked to finasteride use as it occurred 2-3 days after use and stopped upon discontinuation

2017 Drug Safety - Case Reports PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>